Paritaprevir

CAT#: H314255

CAS#: 1216941-48-8

Description: Paritaprevir, also known as ABT-450 or Veruprevir, is an acylsulfonamide inhibitor of the NS3-4A serine protease manufactured by Abbott Laboratories that shows promising results as a treatment of hepatitis C. When given in combination with ritonavir and ribavirin for 12 weeks, the rate of sustained virologic response at 24 weeks after treatment has been estimated to be 95% for those with hepatitis C virus genotype 1. Resistance to treatment with paritaprevir is uncommon, because it targets the binding site, but has been seen to arise due to mutations at positions 155 and 168 in NS3.

img

Synthetic Routes

Paritaprevir - Synthetic Route 1

Paritaprevir route01

Synthetic reference

Caspi, Daniel D.; Cink, Russell D.; Clyne, Dean; Diwan, Moiz; Engstrom, Kenneth M.; Grieme, Timothy; Mei, Jianzhang; Miller, Robert W.; Mitchell, Clifford; Napolitano, Jose G.; Nere, Nandkishor; Ravn, Matthew M.; Sheikh, Ahmad; Wagaw, Seble; Zhang, Hongqiang. Process development of ABT-​450 - A first generation NS3​/4A protease inhibitor for HCV. Tetrahedron. Volume 75. Issue 32. Pages 4271-4286. Journal; Online Computer File. (2019).

Paritaprevir - Synthetic Route 2

Paritaprevir route02

Synthetic reference

Wu, Zhangshuan; Chang, Song; Wang, Zheming; Wei, Yong; Mu, Longzhi; Fan, Zheng. Preparation method of bulk drug paritaprevir. Assignee Anhui Baishancheng Pharmaceutical Co., Ltd., Peop. Rep. China. CN 107383021. (2017).

Paritaprevir - Synthetic Route 3

Paritaprevir route03

Synthetic reference

Ku, Yiyin; McDaniel, Keith F.; Chen, Hui-Ju; Shanley, Jason P.; Kempf, Dale J.; Grampovnik, David J.; Sun, Ying; Liu, Dong; Gai, Yonghua; Or, Yat Sun; Wagaw, Sable H.; Engstrom, Ken; Grieme, Tim; Sheikh, Ahmad; Mei, Jianzhang. Preparation of heterocyclic macrocyclic peptides as hepatitis C serine protease inhibitors. Assignee Enanta Pharjmaceuticals, Inc., USA; Abbott Laboratories. WO 2010030359. (2010).